EDIT Editas Medicine

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

SLEEK results in highly efficient multi-transgene knock-in and enables tunability of transgene expression Double knock-in iNK cells demonstrate strong tumor killing effect and prolonged in vivo persis

05-18 06:51 ET

The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Switzerland Approves Moderna's COVID-19 Shot For Kids 6-11 The Swiss drug regulatory authority has app

05-13 10:43 ET

Today's pre-market stock movers: TSLA, TWTR, AFRM, DWAC and more

Elon Musk tweets "Twitter deal temporarily on hold pending details supporting calculation that spam/fake accounts do indeed represent less than 5% of users"

05-13 08:22 ET · Movers

Editas Medicine Gets FDA Orphan Drug Designation for Blood Disorder Candidate

04:31 AM EDT, 05/13/2022 (MT Newswires) -- Editas Medicine (EDIT) said late Thursday the US Food and Drug Administration has granted orphan drug designation to EDIT-301 for the potential treatment of

05-13 04:35 ET

Editas Medicine granted Orphan Drug Designation for beta thalassemia candidate

The U.S. FDA has granted Orphan Drug designation to Editas Medicine (NASDAQ:EDIT) for EDIT-301, its candidate for beta thalassemia. The company is planning to dose the first person in a phase 1/2 tria

05-12 06:00 ET

Editas Medicine Shares Tick Down 1.5% on EDIT-301 FDA Designation

By Denny Jacob Editas Medicine Inc. shares fell 1.5% to $10.65 in after-hours trading Thursday after it said the Food and Drug Administration granted EDIT-301 orphan drug designation. EDIT

05-12 05:26 ET

Morgan Stanley Lowers Editas Medicine's Price Target to $15 From $17, Underweight Rating Kept

12:45 PM EDT, 05/09/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co

05-09 12:48 ET

Expert Ratings for Editas Medicine

Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 1 2 0 Last 30D 0 0 0

05-09 12:06 ET

Editas Medicine Shares Hit New Low as Morgan Stanley Trims Price Target >EDIT

By Colin Kellaher Shares of Editas Medicine Inc. slid more than 10% and hit a new all-time low in early trading Monday after analysts at Morgan Stanley grew more bearish on the genome-editing

05-09 11:37 ET

Editas Medicine shares are trading lower after Morgan Stanley maintained an Underweight rating on the stock and lowered its price target from $17 to $15.

Editas Medicine shares are trading lower after Morgan Stanley maintained an Underweight rating on the stock and lowered its price target from $17 to $15.

05-09 10:56 ET